COVID-19 and Use of Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin II Receptor Blockers (ARBs)

Allan Brett, MD, Editor-in-Chief, NEJM Journal Watch General Medicine,
Director, Division of General Internal Medicine, Professor of Medicine, University of South Carolina School of Medicine, Columbia, S.C.
Interviewer: Carole Wyand, Medical Anchor, NEJM Journal Watch

In this approximately 8-minute lecture, Allan Brett, MD, Editor-in-Chief, New England Journal of Medicine (NEJM) Journal Watch General Medicine, Director, Division of General Internal Medicine, Professor of Medicine, University of South Carolina School of Medicine, addresses COVID-19 and use of Angiotensin-Converting Enzyme (ACE) inhibitors and Angiotensin II Receptor Blockers (ARBs). Dr. Brett addresses topics ranging from recommendations from professional cardiology societies to how to discuss medications concerns with patients during the COVID-19 pandemic. Dr. Brett was interviewed by NEJM Journal Watch Medical Anchor Carole Wyand. This vital, timely and informative content also offers the opportunity to earn CME credits.

COVID-19 and Use of Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin II Receptor Blockers (ARBs)